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A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim 
to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of 
colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 
2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic 
factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% 
confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use 
was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28–0.79), 
but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use 
(OR: 0.82; 95% CI: 0.47–1.40). A meta-analysis with previous studies suggested a protective effect, 
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overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62–0.97). We have not found strong evidence 
of an independent preventive effect of CG on CRC in our population because the observed effects of our 
study could be attributed to NSAIDs concurrent use. These results merit further research due to the 
safety profile of these drugs.
The high incidence of colorectal cancer (CRC), the known colorectal adenoma-to carcinoma sequence and the 
poor survival rate of advanced CRC has prompted the emphasis on its prevention. Faecal occult blood test has 
demonstrated a reduction of CRC mortality1. This strategy is based on early detection, and requires repeated 
testing to increase sensitivity. Although lifestyle risk factors have been described in CRC aetiology, randomized 
trials have failed to show a reduction of adenomas recurrence with special diets2. Moreover, a safe and effective 
CRC chemoprevention agent has not been found to date in order to reduce the incidence of polyps and/or CRC. 
Acetylsalicylic acid (ASA) is the agent with more evidence and, indeed, the United States Preventive Services 
Task Force3 has recently stated that there is adequate evidence4 that aspirin can be used to reduce risk for CRC 
in adults ages 50 to 69 years who are at increased risk for cardiovascular diseases. However, a general use of this 
drug in younger people or without cardiovascular disease is not recommended because of its adverse events such 
as gastrointestinal and intra-cerebral haemorrhage5. Other drugs and supplements have also been studied as can-
didate chemoprevention agents for CRC such as other non-steroidal anti-inflammatory drugs (NSAIDs)6–8, folic 
acid9,10, calcium10,11, and diverse vitamins10,12. None of them have shown enough evidence to be implemented as 
chemoprevention agents for general population.
Recent evidence suggests that glucosamine and chondroitin sulphate supplements could reduce CRC risk13–15. 
These drugs are widely used in osteoarthritis due to their immunomodulatory effect, which reduces the nuclear 
factor κβ (NF-kβ) translocation. NF-kβ has an established role in the coordination of innate and adaptive 
immune responses and cell-cycle regulation and it has a role in tumorigenesis16. In the VITamins And Lifestyle 
(VITAL)13,14 study and in two prospective cohorts, Kantor et al.15 reported that the use of these drugs had a pro-
tective effect of CRC risk. Moreover, the good tolerability of these drugs has been proven in trials that aimed to 
study the efficacy and safety of chondroitin sulphate plus glucosamine in osteoarthritis17–19. For this reason, we 
wanted to explore the association between glucosamine and chondroitin sulphate and CRC in the MCC-Spain 
case-control study.
Methods
Study population. A Multi Case-control (MCC-Spain) study was performed between 2008 and 2013, in 
which 10183 total subjects aged 20–85 years were enrolled in 12 Spanish provinces. A detailed description has 
been previously published20. The recruitment included incident cases of CRC (C18, C19, C20, D01.0, D01.1, 
D01.2) which were identified through an active search in the participating hospitals. Both cases and controls were 
free of personal CRC history. Controls, selected from the general population, were frequency-matched to cases, 
by age, sex, and region. In this study, we included 2140 cases of CRC and 3950 controls.
All procedures were in accordance with the ethical standards of the institutional and/or national research 
committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. 
The protocol of MCC-Spain was approved by each of the ethics committees of the participating institutions. The 
specific study reported here was approved by the Bellvitge Hospital Ethics Committee with reference PR149/08. 
Written informed consent was obtained from all individual participants included in the study.
Data collection. A structured computerised epidemiological questionnaire was administered by trained 
personnel in a face-to-face interview. This questionnaire included information of sociodemographic factors, 
personal and family medical history, anthropometric data, lifestyle and medication. Also, subjects filled in a 
semi-quantitative Food Frequency Questionnaire (FFQ).
Complete history of regular drug use was recorded, obtained by personal interview, but only chondroitin 
sulphate (ATC code: M01AX25), glucosamine (ATC code: M01AX05) and NSAIDs including non-ASA NSAIDs 
(ATC code: M01A) and ASA (ATC code: B01AC06, N02BA01, NA02BA51) were considered for this study. 
For each drug, the brand name, dose and duration of exposure were recorded. Unless specified, we will refer 
to NSAIDs as the combination of ASA and other NSAIDs. Regular use NSAIDs was defined as consuming ≥1 
times/day for at least one year. However, the low frequency of use of glucosamine or chondroitin sulphate only 
allowed dividing patients into users (either “regular” or “sporadic”) and nonusers. Given that chondroitin sul-
phate and glucosamine are frequently consumed combined and there were few individuals using these drugs, 
their combined use was analysed.
Statistical analysis. A study design adjustment score (SDAS) was built to reduce bias related to differ-
ences in case and control selection frequencies. This SDAS was derived as the prediction of a logistic regres-
sion model on case-control status that included age, sex, recruiting centre and level of education and it also 
included the interactions between age and sex and centre and sex. All analyses were adjusted by the SDAS, and 
multivariable-adjusted analyses also included non-ASA NSAIDs and ASA use, family history of CRC, tobacco 
use, alcohol consumption, BMI (estimated at age 45 years), physical activity, red meat intake and vegetables 
intake. Stratified analyses were also performed to assess the association of chondroitin/glucosamine with CRC 
according to NSAIDs use and BMI, since previous studies suggested a possible interaction with these factors. 
Logistic regression models were used to test for adjusted effects and interactions. Results are reported as odds 
ratios (OR) and 95% confidence intervals (CI). All reported p-values are two-tailed. A fixed-effects meta-analysis 
was performed, combining the estimates from this study with previous published results14,15. Statistical analysis 
was carried out using R statistical software (R Foundation for Statistical Computing, Vienna, Austria).
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Results
Overall, 99 participants (1.63%) reported use of chondroitin sulphate (n = 60) and/or glucosamine (n = 45). 
Table 1 shows the characteristics of chondroitin sulphate and glucosamine users versus non-users among con-
trols. The use of these drugs was only associated with no-ASA NSAIDs consumption (p < 0.001). In contrast, its 
use was independent of sex, age, tobacco use, alcohol consumption, BMI, physical activity, intake of vegetables or 
red meat, and ASA prescription. Regarding other drugs used to treat osteoarthritis, we observed that concurrent 
use of chondroitin sulphate and glucosamine with non-ASA NSAIDs was around 84.9% but with ASA was only 
14.1%. In fact, 98% participants consumed non-ASA NSAIDs as an analgesic drug (30.7% for joint pain and 
67.8% for pain in other locations); 91.7% and 87.5% consumed chondroitin sulphate and glucosamine for a joint 
disease, respectively; and 62.9% subjects were prescribed ASA for primary or secondary prevention of cardiovas-
cular events.
In the crude analysis (only adjusted for the SDAS), chondroitin sulphate and/or glucosamine (CG) use was 
associated with a 53% reduced risk of CRC (OR: 0.47; 95% CI: 0.28–0.79). Both the use of chondroitin sulphate 
alone (OR: 0.42; 95% CI: 0.21–0.84) and glucosamine alone (OR: 0.47, 95% CI: 0.22–1.01) were protective for 
CRC.
In the multivariate-adjusted analysis (Table 2), the use of CG was not significantly associated with CRC 
(adjusted OR: 0.82; 95% CI: 0.47–1.40), probably due to the small number of exposed that limited power, and the 
concurrent use of NSAIDs. Regular use of ASA and non-ASA NSAIDs significantly reduced CRC risk by 25–43% 
in the MCC-Spain study (adjusted OR 0.75; 95% CI: 0.63–0.90, and adjusted OR: 0.54; 95% CI: 0.46–0.65, respec-
tively). Table 3 shows how the protective effect was no longer significant when adjusted for NSAIDs use.
The combined analysis (Table 4) showed that the protective effect of CG on CRC was only among subjects that 
were NSAIDs users. An increased protective effect with concurrent use of CG and NSAIDs was found, suggesting 
a possible additive action.
The fixed-effects meta-analysis of the multivariate-adjusted estimates, both overall (OR 0.77; 95%CI: 0.62–
0.97; p = 0.025) and stratified by NSAID use (OR for NSAID users 0.73; 95%CI: 0.54–0.98; p = 0.036. OR for 
Characteristic
Nonusersa Users
P-valuebn (%) n (%)
Age (years)
 26–65 2066 (53.4) 39 (48.8)
 65–85 1804 (46.6) 41 (51.3) 0.41
Sex
 Female 1886 (48.7) 46 (57.5)
 Male 1984 (51.3) 34 (42.5) 0.12
Smoking
 Non-smoker 1721 (44.5) 42 (52.5)
 Former/Current smoker 2149 (55.5) 38 (47.5) 0.15
Alcohol
 Low consumption 3315 (85.7) 66 (82.5)
 High consumption 555 (14.3) 14 (17.5) 0.43
BMI at 45-year age
 <25kg/m2 2225 (57.5) 54 (67.5)
 ≥25kg/m2 1645 (42.5) 26 (32.5) 0.80
Physical activity in leisure time
 No 1623 (41.9) 26 (32.5)
 Yes 2247 (58.1) 54 (67.5) 0.09
Vegetables
 ≤200g/day 2564 (66.3) 54 (67.5)
 >200g/day 1306 (33.8) 26 (32.5) 0.81
Red meat
 ≤65g/day 2269 (58.6) 52 (65.0)
 >65g/day 1601 (41.4) 28 (35.0) 0.25
ASA
 Nonuser/sporadically use 3386 (87.5) 66 (57.5)
 Regular use in the last year 484 (12.5) 14 (17.5) 0.19
Non-ASA NSAIDs
 Nonuser/sporadically use 3200 (82.7) 11 (13.8)
 Regular use in the last year 670 (17.3) 69 (86.3) <0.0001
Table 1. Characteristics of the chondroitin sulphate and glucosamine users in controls. aUser includes 
sporadically use and regular use. bP-values derived from a chi-square test. ASA: acetylsalicylic acid; BMI: body 
mass index; CRC: colorectal cancer; NSAID: Nonsteroidal anti-inflammatory drugs.
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non-NSAID users 0.71; 95%CI: 0.51–0.99; p = 0.049) confirmed a significant protective effect of CG in CRC 
(Fig. 1). No evidence of heterogeneity was observed (estimated heterogeneity variance = 0.01, p = 0.99; test for 
funnel plot asymmetry: z = 0.052, p = 0.96).
Discussion
The results of this case-control study did not show clear evidence of a preventive effect of CG on CRC because, 
though in the univariate analysis CG had a significant association, this effect was no longer significant when 
adjusted for NSAID use. The number of subjects exposed to CG was low, and this reduced the power to detect a 
Characteristic
Controls Cases Adjusted
95% CI P-Valuen % n % ORa
Family history of CRC
 No 3483 (88.2) 1663 (77.7) 1.00
 Yes 467 (11.8) 477 (22.3) 2.43 2.09–2.83 <0.0001
Smoking
 Non-smoker 1763 (44.6) 893 (41.7) 1.00
 Former/Current smoker 2187 (55.8) 1247 (58.3) 1.05 0.93–1.84 0.43
Alcohol
 Low consumption 3381 (85.6) 1685 (78.7) 1.00
 High consumption 569 (14.4) 455 (21.3) 1.35 1.16–1.57 <0.0001
BMI at 45-year age
 <25kg/m2 2279 (57.7) 982 (45.9) 1.00
 ≥25kg/m2 1671 (42.3) 1158 (54.1) 1.16 1.03–1.30 0.01
Physical activity in leisure time
 No 1649 (41.8) 1101 (51.5) 1.00
 Yes 2301 (58.3) 1039 (48.6) 0.70 0.63–0.78 <0.0001
Vegetables
 ≤200g/day 2618 (66.3) 1526 (71.3) 1.00
 >200g/day 1332 (33.7) 614 (28.7) 0.75 0.66–0.85 <0.0001
Red meat
 ≤65g/day 2321 (58.8) 1070 (50.0) 1.00
 >65g/day 1629 (41.2) 1070 (50.0) 1.22 1.09–1.38 0.0008
ASA
 Non-user/sporadically use 3452 (87.4) 1894 (88.5) 1.00
 Regular use in the last year 498 (12.6v 246 (11.5) 0.75 0.63–0.90 0.0013
Non-ASA NSAIDs
 Non-user/sporadically use 3181 (80.5) 1912 (89.4) 1.00
 Regular use in the last year 769 (19.5v 228 (10.7) 0.54 0.46–0.65 <0.0001
Chondroitin and/or glucosamine
 Non-user 3870 (98.0) 2121 (99.1) 1.00
 Userb 80 (2.0v 19 (0.9) 0.82 0.47–1.40 0.37
Table 2. Multivariate-adjusted risk factors associated with CRC. aAdjusted by the study design adjustment 
and the variables shown in this table. ASA: acetylsalicylic acid; BMI: Body mass index; CRC: colorectal cancer; 
NSAID: Nonsteroidal anti-inflammatory drugs.
OR 95% CI P-value
Crude effecta 0.47 0.28–0.79 0.0023
Adjusted for ASA use 0.47 0.28–0.79 0.0045
Adjusted for non-ASA 
NSAIDs use 0.72 0.43–1.23 0.23
Adjusted for NSAIDs use 0.62 0.37–1.05 0.077
Adjusted for multivariateb 
without NSAIDs use 0.52 0.31–0.88 0.017
Adjusted for multivariateb 0.82 0.47–1.40 0.37
Table 3. Chondroitin sulphate and glucosamine association to risk of CRC. aAdjusted by the study design 
variables (age, gender, region and education). bAdjusted by the study design variables plus alcohol consumption, 
BMI, physical activity, vegetables and red meat intake, family history and NSAIDs use (see Table 3). ASA: 
acetylsalicylic acid; NSAID: Nonsteroidal anti-inflammatory drugs (includes ASA except when indicated).
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protective effect. The analysis stratified by NSAIDs use indicated that the effect of CG was additive to the concur-
rent use of these drugs (Table 4).
The OR for CG was no longer significant when adjusted for NSAIDs use but the magnitude of the adjusted 
effect was similar to that reported recently by Kantor et al.15 in two prospective cohorts in North America (RR: 
0.77; 95% CI: 0.58–0.99). Previously, Satia et al.13 already observed in an exploratory analysis within the VITamins 
Control Case
Interaction analysis between chondroitin and/or glucosamine use and NSAIDs
n % n % Adjusted ORa 95% CI
CG nonuserb - 
NSAIDs nonuserc 2776 70.28 1697 79.30 1.00
CG user - NSAIDs 
nonuser 10 0.250 4 0.19 1.04 0.31–3.55
CG nonuser - 
NSAIDs user 1094 27.70 414 19.81 0.62 0.53–0.71
CG user - NSAIDs 
user 70 1.77 15 0.70 0.40 0.22–0.72
Stratified analysis of chondroitin and/or glucosamine protective effect of CRC according to NSAID use
n % n % Adjusted ORa 95% CI p-interaction
NSAIDs nonuser 0.50
  CG nonuser 2803 99.64 1715 99.77 1
  CG user 10 0.36 4 0.23 1.04 0.30–3.54
NSAIDs userc
  CG nonuser 1067 93.84 406 96.44
  CG user 70 6.16 15 3.56 0.66 0.37–1.21
Table 4. Analysis of chondroitin and/or glucosamine protective effect of CRC according to NSAID use 
aAdjusted by the study design variables (age, gender, region and education) plus alcohol consumption, BMI, 
physical activity, vegetables and red meat intake, family history and NSAIDs. bUser includes sporadically use 
and regular use. cUser includes only regular use of NSAIDs. CG: chondroitin and/or glucosamine. NSAID: 
Nonsteroidal anti-inflammatory drugs (including ASA).
Odds ratio
0.25 0.40 0.63 1.00 1.58 2.51 3.98
Overall
               VITAL
               NHS+HPS
               MCC−Spain
     summary:                                                                                       OR=0.77 (0.62−0.97) p=0.025
NSAIDs No
               VITAL
               NHS+HPS
               MCC−Spain
     summary:                                                                                       OR=0.71 (0.51−0.99) p=0.049
NSAIDs Yes
               VITAL
               NHS+HPS
               MCC−Spain
     summary:                                                                                       OR=0.73 (0.54−0.98) p=0.036
Figure 1. Meta-analysis of studies of chondroitin sulphate and glucosamine and the risk of CRC. Estimated 
heterogeneity variance = 0.01, P = 0.99.
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And Lifestyle (VITAL) study that use of glucosamine (HR: 0.72; 95% CI, 0.54–0.98) and chondroitin sulphate 
(HR, 0.65; 95% CI, 0.45–0.93) supplements were associated with reduced risk of CRC after 5 years of follow-up. 
These results were not statistically significant when adding two years of follow-up (HR: 0.55; 95 % CI 0.30–1.01)14. 
Despite the fact that we could not find an association of CG with CRC risk that was independent of NSAID use, 
all the above-mentioned studies13,15 did control for ASA and NSAIDs and they did find an independent effect. 
In fact, our meta-analysis of the VITAL study14, the Nurses’ Health Study and Health Professionals follow-up 
study15 and the MCC-Spain showed a significant overall effect, multivariate-adjusted, which was also significant 
both for concurrent non-NSAID users and for NSAID users (Fig. 1). The lack of heterogeneity among the studies 
reinforced the observed protective effect.
Though glucosamine and chondroitin sulphate have anti-inflammatory effect, its mechanism is independent 
of cyclooxygenase-2 inhibition and the anti-inflammatory mechanism is thought to be independent of NSAIDs. 
However, our stratified analysis by NSAID use does not seem to support this, as the inverse association with 
chondroitin sulphate and glucosamine was seen only among NSAID users. Because of the low number of CG 
users, we could not analyse duration and time exposure, so we could not differentiate concomitant and sequential 
exposure of CG and NSAIDs. We do not know if the increased protection of CG and non-ASA NSAIDs or ASA 
use was because of CG itself or because this subgroup used a higher dose or longer period use of NSAIDs.
In vitro and animal studies14,15,21–24 suggest that this protective effect might be caused through reduction in 
inflammation25–27 by the suppression of the NF-kβ pathway16, this alternative mechanism is relevant and explains 
the better toxicity profile of glucosamine and chondroitin sulphate observed in multiple clinical trials28. We 
should highlight that glucosamine increases insulin resistance in skeletal muscle and diabetics should take cau-
tion when taking it, however, alteration of glucose homoeostasis was not found in a 3-year randomised controlled 
study in patients without diabetes29. Moreover, some preparations that contain glucosamine extracted from sea-
food could increase the risk of hypersensitivity reactions among people with an allergy to shellfish30,31. A 2006 
Cochrane systematic review32 concluded that glucosamine is as safe as placebo and Matheson et al.33 reported less 
gastrointestinal symptoms, skin reactions or fatigue with glucosamine than ibuprofen. As for chondroitin sul-
phate, it is considered to be safe, with rare incidence of adverse reactions which suggests its long term safety28,31,34. 
Only mild gastrointestinal side effects such as nausea, diarrhoea or constipation, stomach pain, and heart burn 
have been reported34.
Previous studies13,14 had controversial results of the association of chondroitin sulphate and glucosamine to 
CRC according to BMI. We did not find any evidence of an effect modification of CG by BMI, though we had 
limited power to detect this interaction. The OR for CG was 0.67 (95%CI: 0.29–1.56) for BMI ≥25kg/m2 and 0.76 
(95%CI: 0.37–1.48) for BMI <25kg/m2.
This study has several limitations that might explain the low prevalence of use of chondroitin sulphate and 
glucosamine (1.63%). First, drug consumption was self-reported, which could introduce a recall bias and atten-
uate the association observed. Although we wanted to recollect detailed information of dosages and prescription 
duration, we could not analyse the dose-effect relationship because patients did not provide enough detailed 
data regarding drugs consumption. The reported prevalence of use in the USA was 13%15, a country in which 
these drugs can be self-purchased as nutritional supplements, while in Spain a prescription is required. Also, the 
mean age of our population (64.6 years, range 22–85) is a few years younger and with less women (44.4%) than 
previous studies14,15, which reduces the prevalence of subjects with osteoarthritis. In fact, it is reported that the 
highest prevalence of knee pain is amongst women aged 7535. There could be also surveillance bias as patients 
with osteoarthritis are in the same age range as CRC. Patients with osteoarthritis have regular medical visits that 
could result in increased screening for CRC, early intervention for polyp removal and prevention of actual CRC. 
Another concern is the confounding by association with NSAIDs as chondroitin sulphate and glucosamine are 
used essentially for osteoarthritis, and generally with NSAIDs, so the univariate analysis could essentially repre-
sent the effect of concomitant NSAIDs that have already demonstrated a protective effect7,36. The fact is that in the 
very few patients without NSAIDs there is no effect of CG on CRC. The increased effect when CG is associated 
with NSAIDs could simply be a dose effect of NSAIDs, if CG use selected patients with more severe osteoarthritis 
(a higher dose or longer period use of NSAIDs). To address these limitations, larger studies, preferably with pro-
spective design and with exposure assessment based on registered data, should be performed.
In conclusion, we have not found clear evidence of an independent preventive effect of CG on CRC because 
the observed effects of our study could be attributed to NSAIDs concurrent use. However, the good toxicity pro-
file merits further research to examine their effect and a potential role as chemopreventive agents.
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